Cargando…
MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation
Hypermethylation of the MGMT gene promoter and mutation of the TP53 tumor-suppressor gene are frequently present in diffuse astrocytomas. However, there is only anecdotal information about MGMT methylation status and TP53 mutations during progression of low-grade diffuse astrocytoma (AII) to anaplas...
Autores principales: | Groenendijk, Floris H., Taal, Walter, Dubbink, Hendrikus J., Haarloo, Cathleen R., Kouwenhoven, Mathilde C., van den Bent, Martin J., Kros, Johan M., Dinjens, Winand N. M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024495/ https://www.ncbi.nlm.nih.gov/pubmed/20593220 http://dx.doi.org/10.1007/s11060-010-0274-x |
Ejemplares similares
-
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951
por: Idbaih, Ahmed, et al.
Publicado: (2010) -
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021) -
Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples
por: Mankor, Joanne M., et al.
Publicado: (2020) -
TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer
por: Vitale, Silvia R., et al.
Publicado: (2020) -
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients
por: Quillien, Véronique, et al.
Publicado: (2014)